CATX
AMEX · Biotechnology
Perspective Therapeutics Inc
$0.87
0.00 (-0.14%)
Open$0.87
Previous Close$0.87
Day High$0.87
Day Low$0.86
52W High$6.16
52W Low$0.84
Volume—
Avg Volume5.16M
Market Cap95.89M
P/E Ratio—
EPS$-1.33
SectorBiotechnology
Analyst Ratings
Strong Buy
21 analysts
Price Target
+2,163.5% upside
Current
$0.87
$0.87
Target
$19.67
$19.67
$12.33
$19.67 avg
$23.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.32M | 2.10M | 70.28M |
| Net Income | -154,159,132 | -220,542,391 | -10,926,196 |
| Profit Margin | -11,665.3% | -11,082.0% | -15.6% |
| EBITDA | -164,906,466 | -249,024,229 | -18,107,687 |
| Free Cash Flow | — | — | -6,087,830 |
| Rev Growth | -37.1% | -37.1% | +8.8% |
| Debt/Equity | 0.01 | 0.01 | 0.76 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |